|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||132.38 - 133.78|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.29|
|Dividend & Yield||3.36 (2.53%)|
|1y Target Est||N/A|
Here's why I think Johnson & Johnson, Medtronic, and Omega Healthcare Investors will continue to deliver outsized returns for the rest of my days.
A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding. The verdict in U.S. District Court in Jackson, Mississippi, is a blow to thousands of patients with similar allegations against the drugmaker. In the latest case, plaintiff Dora Mingo claimed she suffered acute gastrointestinal bleeding after she was treated with Xarelto for a month in 2015 to prevent blood clotting following an operation.